Influence of fixed combination perindopril and indapamide on heart and vascular remodeling in hypertensive patients
Abstract
Aim. To evaluate antihypertensive efficacy of fixed combination: perindopril 4 mg/d plus indapamide 1.25 mg/d, and its influence on cardiovascular remodeling in untreated hypertensive patients.
Material and methods. The study included 25 previously untreated patients with arterial hypertension (mean age 48.1±2,7 years; 13 males, 12 females). The effects of 6-month perindopril/indapamide combined therapy on daily blood pressure (BP), left ventricular (LV) hypertrophy, carotid intima-media thickness (IMT), pulse wave velocity (PWV), and cerebral blood flow velocity were investigated.
Results. Target BP level was achieved in 77% of the patients. BP monitoring demonstrated significant reduction in systolic BP (daytime: -9.4%, p<0.001; nighttime: -10.4%, p<0.001) and diastolic BP (-10.6%, p<0,001; -9.9%, p<0.001, respectively). Substantial reduction of LV mass index (-12%, p=0.005) was observed. LV posterior wall and interventricular septal thickness were reduced by 7.6% (p<0.004) and 9.5% (p=0.001), respectively. Carotid IMT decrease (-12.1%, p<0.001) and arterial stiffness reduction in elastic arteries (carotid-femoral PWV decreased by 11.3%, p=0.0001) were registered. Cerebral blood flow velocity, normal at baseline, did not change.
Conclusion. Treatment with a fixed combination of perindopril and indapamide in hypertensive patients is characterized by high antihypertensive efficacy, metabolic neutrality, and positive influence on remodeling of both the heart and large and medium arteries.
About the Authors
Yu. M. LopatinRussian Federation
T. D. Каplanov
Russian Federation
V. V. Ivanenko
Russian Federation
N. V. Ryazantseva
Russian Federation
A. V. Legky
Russian Federation
L. P. Anisimova
Russian Federation
References
1. Guidelines Committee. 2003 European Society of Hypertension – European Society of cardiology Guidelines for the management of Arterial Hypertension. J Hypertens 2003; 21: 1011-53.
2. Второй пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваск тер профил 2004; 3(3), ч. I: 105-20.
3. Chanudet X, Phong Chau N, De Champvallins M. Very low-dose perindopril 2 mg/indapamide 0,625 mg combination gives higher response and normalization rates than losartan 50 mg in the treatment of essential hypertension. Am J Hypertens 2000; 4: 140A.
4. Morgan T, Anderson A. Low dose combination therapy (perindopril, indapamide) compared with irbesartan monotherapy. J Hypertens 2001; 19 (Suppl.2): S235.
5. Mogensen CE, Viberti G, Halimi S. Treatment based on a low dose combination of per-indopril and indapamide reduces albuminuria more effectively than enalapril in hyper-tensive type 2 diabetic patients. Am J Hypertens 2002; 15: 21A-2.
6. De Luca N, Safar ME, Asmar R, et al. Efficacy of a very lowdose perindo-pril2mg/indapamide 0.625 mg on cardiac hypertrophy in hypertensive patients: the REASON project. J Hypertens 2002; 20 (Suppl. 4): S164.
7. Asmar RG, London GM, O’Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a verylow-dose perindopril/indapamide combination in hypertensive patient. A comparison with atenolol. Hypertension 2001; 38: 922-6.
8. Лопатин Ю.М., Иваненко В.В., Семенова Н.В. и др. Влияние фиксированной низкодозовой комбинации периндоприла/индапамида на процессы сердечно-сосудистого ремоделирования у ранее не леченных пациентов с артериальной гипертонией. Кардиология 2004; 5: 48-53.
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evalua-tion, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.
10. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613-8.
Review
For citations:
Lopatin Yu.M., Каplanov T.D., Ivanenko V.V., Ryazantseva N.V., Legky A.V., Anisimova L.P. Influence of fixed combination perindopril and indapamide on heart and vascular remodeling in hypertensive patients. Cardiovascular Therapy and Prevention. 2005;4(1):20-25. (In Russ.)